FXI Holdings: A Not-so-Soft Landing

Welcome to the 185th Pari Passu newsletter.

FXI Holdings is the largest polyurethane foam manufacturer in North America, operating 34 facilities across the U.S. and Mexico. In 2017, One Rock Capital Partners acquired FXI and merged it with Bain Capital's Innocor in 2020, loading over $1.3bn of debt onto a combined platform whose earnings peaked during a pandemic-driven demand surge and have been declining ever since. Two distressed exchanges later, taking place in 2023 and 2025, total funded debt is higher than when the distress began.

What makes FXI's story especially interesting is what the creditors negotiated in response. The 2025 LME introduced a "hand-the-keys" provision into the post-LME credit docs, only the second known instance of this mechanism in the broadly syndicated market, which we’ll take a deep dive into. In a market where more and more LMEs end up back where they started, the FXI deal offers a new answer to an increasingly common question: what happens when an LME doesn't work?

In today's writeup, we'll start by overviewing FXI's business model and the polyurethane foam industry. From there, we'll trace the company's corporate history from its roots through the One Rock acquisition and Innocor merger. We'll then walk through the path to distress, covering the 2022 demand collapse, the 2023 exchange that kicked the can, and the return to distress that followed. We'll end by breaking down the 2025 LME, its novel post-LME docs, and what the transaction means for the evolving LME landscape.

FXI Holdings is a vertically integrated manufacturer of polyurethane foam. Polyurethane (PU) foam is inside the sofa you are sitting on, the headrest in your car, and the padding inside the packaging that shipped your last online order. Before we get into FXI's history and the transactions that followed, it's worth understanding what PU foam actually is and why it matters. The material is produced by mixing two petroleum-derived chemicals, polyols and diisocyanates, in a reaction that causes the liquid to expand and harden into a cellular structure. By adjusting the chemistry, temperature, and processing conditions, manufacturers can produce foam ranging from ultra-soft pillow fill to the dense memory foam that transformed the mattress industry over the past two decades. The global polyurethane foam market was valued at roughly $50bn in 2024, with bedding and furniture alone accounting for nearly a third of total demand.

FXI Holdings exists because manufacturing polyurethane foam at scale is harder than it looks, as the production process requires specialized equipment and strict environmental controls. Additionally, the finished product is bulky and expensive to ship relative to its value, which means proximity to customers matters enormously. These characteristics favor large, regionally distributed manufacturers that can produce foam near end users while spreading fixed costs over high volumes. FXI is the dominant player in this niche. 

Headquartered in Radnor, Pennsylvania, the company operates 34 manufacturing and distribution facilities across the United States and Mexico, employing approximately 4,150 people. The company describes its model as "molecule-to-doorstep" vertical integration, meaning it controls every step from raw chemical processing, foam formulation, finished product manufacturing, and, in many cases, direct retail distribution. That integration, combined with a portfolio of over 400 active patents, creates meaningful barriers to entry [1].

While FXI serves four end markets, two of them drive the vast majority of revenue [1]. To start, retail bedding is the company’s highest-margin segment and main driver of growth. The segment includes FXI's portfolio of branded consumer products, including the Novaform mattress line sold through Costco and Walmart, the Sleep Innovations brand, and the newer Molecule performance sleep collection. In recent years, FXI has increasingly focused on capturing shelf space in big-box retail and e-commerce with its own finished mattresses, toppers, and pillows, rather than simply selling raw foam as a component. Next, OEM bedding and furniture is the historically larger but lower-margin side of the business, in which FXI supplies raw and semi-finished foam to mattress manufacturers and furniture makers. This segment generates higher volumes but operates at considerably thinner margins, with pricing driven largely by raw material pass-throughs and competitive dynamics among domestic foam producers. Beyond these two core segments, the company's engineered solutions business supplies specialty foam for automotive interiors, surgical positioning products, filtration, and acoustic management. Lastly, the smaller transportation segment provides comfort and safety foam for aviation and vehicle seating.

A key aspect of FXI's business model to highlight is the cyclicality of its end markets. In particular, bedding and furniture are highly discretionary purchases. When the economy softens, consumers defer mattress replacements and furniture upgrades, and they tend to do so abruptly. The U.S. mattress market experienced a pronounced pull-forward in demand in 2020 and 2021 as homebound consumers upgraded their sleeping and living environments. The correction that followed was equally sharp, and the industry has remained in a prolonged trough as elevated interest rates, weak housing turnover, and low consumer confidence have all kept mattress replacement cycles extended. 

Lastly, it's important to understand the relationship between FXI's domestic manufacturing footprint and its fixed-cost structure. In a normal demand environment, having 34 facilities distributed across North America is a competitive advantage for a bulky, low-value-to-weight product. Proximity to customers reduces freight costs, enables short lead times, and balances production across regional hubs. However, that same footprint becomes a liability when volumes decline, because manufacturing overhead, labor, and facility costs do not scale down proportionally with lower throughput. These two dynamics, cyclicality and operating leverage, are common themes among our recent coverage and will play a large role in FXI’s story. 

FXI's roots trace back to its predecessor, Foamex International. Foamex was the product of a foam-manufacturing rollup strategy executed by Marshall Cogan, a former Wall Street dealmaker, during the 80s and 90s. Foamex grew over several decades into one of the largest flexible foam producers in North America, operating across carpet cushion, furniture, automotive, and consumer product categories. Foamex's history is also a story of chronic overleveraging. The company filed for Chapter 11 in September 2005 with over $744mm in debt, ultimately converting $523mm of senior secured notes into equity in order to emerge in early 2007. That clean balance sheet didn't last. Less than two years later, in February 2009, Foamex filed for bankruptcy a second time, this time crushed by collapsing demand in the auto and housing markets during the financial crisis [2]. 

The second bankruptcy ended differently, and Foamex was sold through a 363 sale process. In June 2009, MatlinPatterson and Black Diamond Capital Management acquired substantially all of Foamex's assets, and the company re-emerged as a privately held entity under a new name: FXI-Foamex Innovations [3]. The new owners inherited a business that had been right-sized through two bankruptcies but still retained a strong foothold across the U.S. and Mexico. Over the next eight years under MatlinPatterson and Black Diamond's ownership, FXI stabilized its operations and rebuilt its market position as a leading domestic foam manufacturer. 

Then, in September 2017, One Rock Capital Partners acquired FXI from MatlinPatterson and Black Diamond for approximately $700mm [4]. While additional financial details were not disclosed, we estimate $60-70mm of EBITDA, implying a purchase multiple in the low teens. One Rock funded the deal with $525mm of 7.875% senior secured notes due 2024. At the time, FXI still operated 18 facilities, down from 31 in the Foamex era, and generated revenue primarily through its OEM foam business, with a smaller but growing consumer products division. One Rock's thesis centered on operational improvement and growth in what it described as a company with strong market positioning and an attractive product pipeline [4]. 

The next transformative event came in early 2019 when FXI announced a merger with Innocor [5]. Innocor, a vertically integrated foam manufacturer with an established branded retail line, was founded in 1996 and is headquartered in Red Bank, New Jersey. The company was formed through Sun Capital Partners' 2012 acquisition of Sleep Innovations, a specialty mattress manufacturer, followed by a 2014 acquisition of Flexible Foam Products, a raw foam producer. Sun Capital merged the two businesses into a single entity, creating the second-largest flexible PU foam producer in North America, with 21 manufacturing plants and a portfolio of consumer brands, including Novaform (exclusive to Costco) and Sleep Innovations. In December 2016, Bain Capital acquired Innocor from Sun Capital, maintaining the existing management team and continuing to invest in the company's retail-facing product lines [6].

Under the FXI-Innocor merger, One Rock owned 74% of the combined entity while Bain Capital retained 26% ownership [5]. While the transaction’s valuation was not disclosed, industry publications estimate the combined company was valued at approximately $2bn [20]. The transaction was supported by the issuance of $775mm of 12.25% SSSns due November 2026, layered on top of the SSNs from the original LBO. When the deal was marketed to investors in late 2019, the company projected substantial synergies from operational improvements, volume consolidation, and logistics optimization. Notably, the FTC attempted to block the deal, as FXI and Innocor were two of five major low-density foam suppliers in the U.S. [5]. However, FTC approval eventually came in February 2020 after FXI and Innocor agreed to divest three plants to competitor Future Foam to address antitrust concerns, and the merger closed shortly thereafter [8]. The merger nearly doubled FXI's facility count to 34 locations, grew the employee count to nearly 4,000, and pushed combined annual revenue well above $1.5bn [8], [1]. Importantly, it brought Innocor's high-margin branded retail business, particularly the Novaform and Sleep Innovations mattress lines, under the same roof as FXI's larger but lower-margin OEM foam operations.

Notably, the company marketed $72mm of the projected synergies we mentioned above, which would have reduced pro forma leverage to 5.5x. [21]. However, immediately following the merger, which closed in February 2020, and before COVID-related tailwinds revealed themselves, S&P initially estimated post-merger leverage at 8.0x [9]. With $1.3bn in funded debt, this implies roughly $163mm of pro forma adj. EBITDA before assuming the realization of any synergies. At this level, we estimate the merger valued the combined entity at roughly 12x PF 2020E EBITDA of $163mm. As a reminder, these figures reflect our estimates rather than company disclosures. 

Shortly after the deal closed, upon the onset of the COVID-19 pandemic, the deal appeared to be a home run. During 2020 and 2021, homebound consumers spent aggressively on bedding and home furnishings, creating a demand surge that temporarily masked FXI’s aggressive post-merger leverage. EBITDA margins expanded as volume growth, cost-reduction initiatives, and synergies from the Innocor integration all contributed to improved performance. Revenue peaked at $1.65bn and, at that time, leverage had improved to 6.5x, implying roughly $200mm of adj. EBITDA [9]. However, the demand environment that supported those metrics was unsustainable. Consumers had pulled forward years of mattress and furniture purchases into a compressed window, and when spending rotated away from discretionary purchases in 2022, the correction was severe.                  

In 2022, FXI's OEM bedding and furniture segment experienced double-digit volume and sales declines as the broader mattress industry entered what would become a multiyear downturn. Retail bedding held up somewhat better, with sales down only slightly, though volumes still fell in the mid-single digits [10]. At the same time, raw material costs spiked sharply in the first half of 2022 as polyol and isocyanate prices followed energy markets higher. FXI's pass-through pricing contracts provided some protection, but pricing adjustments lagged the pace of input cost increases, and margins still compressed. By mid-2022, free cash flow had turned negative. 

To put perspective on FXI’s financial position, consider that FXI carried $1.3bn of debt with a fixed blended interest rate of 10.5%. Therefore, every year, FXI footed $136mm in cash interest expense, excluding any ABL balance. When EBITDA was at its $200mm peak, that interest load was uncomfortable but manageable, representing interest coverage of roughly 1.5x. However, as EBITDA started declining, the fixed interest burden directly translated to reduced free cash flow. With negative FCF, FXI became reliant on its $235mm ABL, which at the time still had ample capacity, to cover its cash deficit. 

Compounding FXI’s cash generation issues was the impending maturity of its 7.875% notes in November 2024. While this maturity was still two years away, FXI’s ABL contained a springing maturity that significantly accelerated the need to refinance.  FXI’s ABL came due on the earlier of February 2025 or 90 days before the most current senior secured note comes due, meaning the ABL was effectively due August 2024, adding another layer of complexity to a potential refinancing. Ultimately, FXI couldn’t just rely on its ABL facility to bridge its temporary cash flow issues, but would instead have to address a larger incoming maturity wall, leading us to the 2023 exchange.  

In March 2023, FXI entered into a transaction support agreement with holders of approximately $395mm, or 78%, of the outstanding 2024 notes. The exchange launched in early April and closed on May 1, 2023. 

The mechanics of this exchange were relatively straightforward compared to what would come later. FXI offered to exchange each $1,000 of existing 7.875% notes due 2024 for $940 in principal amount of newly issued 12.25% SSNs due November 2026, plus $60 in cash. Holders who exchanged by the early deadline also received a $40 consent fee, bringing their total cash consideration to $100 and total recovery to $1,060 (above par). Late tenders received only the $60 cash payment without the consent fee, equating to a par recovery. The new 12.25% notes were issued with the same collateral package as the existing 2026 tranche and ranked pari passu with them, though notably with a tighter covenant package that included additional restrictions on restricted payments and IP transfers to unrestricted subsidiaries [11]. Alongside the exchange, FXI conducted a consent solicitation to strip the remaining 2024 notes of substantially all restrictive covenants, default provisions, and collateral [11]. The consent solicitation, combined with the transaction economics, made non-participation especially unattractive. Consequently, the transaction ended up achieving 99.1% participation, or $500mm of the outstanding 2024 notes. Just $4.5mm of 2024 notes remained outstanding, and were now subordinated and stripped of covenants. 

To fund the cash component of the exchange and the consent fees, One Rock and Bain arranged a $50mm equity investment in the form of preferred stock, which was contributed down through the corporate structure to FXI as common equity. This sponsor contribution was effectively deleveraged by a small amount since each $1,000 of tendered notes produced only $940 of new notes. The net result of the transaction was a consolidated capital structure that now fully came due in November 2026, comprised of the original $775mm 12.25% notes, and $470mm of the newly issued 12.25% SSNs. Lastly, while the transaction was able to push out maturities, it's important to note that it raised FXI’s average interest rate to 12.25%, and increased cash interest expense from $136mm to $153mm. While the headline coupon increased from 7.875% to 12.25%, a portion of that change reflects the broader rate environment. Base rates rose from roughly ~2% in late 2017 to ~4.5% by early 2023, implying that the underlying credit spread still widened by approximately 200 basis points, which means capital markets were clearly underwriting a higher-risk credit profile for FXI.

Following the exchange, FXI's operating performance improved modestly in 2023, with the company outperforming the subdued bedding market through new retail business wins and increased aisle share with key customers [12]. However, the improvement wasn't nearly enough, and the OEM bedding and furniture segment continued to face lower volumes and pricing pressure. As a result, leverage sat at 8.5x, implying just $147mm of adj. EBITDA, a 27% decline from the COVID-era peak [12]. Notably, following the recent exchange, FXI’s $153mm cash interest burden now consumed virtually all EBITDA, and when combined with capex and working capital requirements, resulted in an even larger cash deficit. Given its interest burden and fixed cost base, FXI would need a material rebound in demand in the coming years to become cash positive again. 

Unfortunately, in 2024 and 2025, the demand environment that FXI needed simply didn’t materialize. The U.S. mattress market remained stuck in a prolonged trough. Housing turnover, one of the primary drivers of mattress replacement purchases, stayed depressed as elevated mortgage rates locked homeowners into their existing properties. Additionally, a notable industry development added competitive uncertainty. In early 2025, the largest U.S. bedding manufacturer, Tempur Sealy International, acquired the largest U.S. bedding retailer, Mattress Firm, representing a consolidation event that analysts flagged as a potential headwind for FXI's competitive positioning [13]. Performance continued to deteriorate in 2025, driven by persistent demand softness and competition in the OEM segment, with retail now slightly down as well.

By mid-2025, LTM revenue had fallen to $1.3bn, down from its $1.65bn peak in 2021 [14]. Additionally, EBITDA had fallen to roughly $138mm as leverage reached approximately 9.0x [14]. This outsized decline in EBITDA is a clear example of operating leverage working in reverse, as FXI struggled to fill its 34 manufacturing facilities amidst sustained volume declines. As a result, free cash flow remained deeply negative, with Moody’s estimating roughly $35mm of cash burn for the full year 2025 [18]. Over the past two years, FXI had been drawing on its ABL facility to bridge this gap, which had been downsized to $187mm following a December 2023 amendment. While FXI made its $76mm semiannual interest payment in May 2025, there was a substantial risk of a liquidity event approaching the November payment, as the company now had just $23mm available under its ABL facility. It was clear that FXI would need to negotiate a comprehensive capital structure solution.

By October 2025, FXI had retained Latham & Watkins and Perella Weinberg to negotiate with lenders, who, in turn, had retained Houlihan Lokey and Paul Weiss [16]. At the time, the company's $775mm and $470mm tranches of 12.25% notes were both trading at roughly 88 cents [16]. Without a restructuring, the company would not be able to service its November 2025 interest payment, let alone address the 2026 maturity wall. The stage was set for a second LME.

On October 30, 2025, FXI launched its second debt exchange. This transaction was materially more complex than the 2023 deal, and we’ll walk through each component.